SCHEMBL6423852

SCHEMBL6423852

CCOc1ccc(C(Cl)(c2ccccc2)c2ccc(OCC)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.57
KIF11 P52732 1/20 0.55
NQO1 P15559 1/20 0.54
RELA Q04206 1/20 0.52
TSHR P16473 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
ALDH1A1 P00352 2/20 0.45
TP53 P04637 2/20 0.45
HPGD P15428 2/20 0.45
KDM4E B2RXH2 1/20 0.45
POLB P06746 1/20 0.45
GAA P10253 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7865523 1.00 LTA4H (0.57) LTA4HKIF11NQO1RELATSHR
SCHEMBL12128744 0.82 SMN1; SMN2 (0.64) LTA4HKIF11NQO1RELATDP1
SCHEMBL18302044 0.81 LTA4H (0.60) LTA4HTSHRSMN1; SMN2ALDH1A1TP53
SCHEMBL9304906 0.81 LTA4H (0.60) LTA4HTSHRSMN1; SMN2ALDH1A1TP53
SCHEMBL6566848 0.81 LTA4H (0.57) LTA4HKIF11NQO1RELATSHR
SCHEMBL121800 0.78 CA4 (0.54) LTA4HKIF11TSHRTDP1SMN1; SMN2
SCHEMBL26862 0.78 CA4 (0.54) LTA4HKIF11TSHRTDP1SMN1; SMN2
SCHEMBL16698731 0.78 CA4 (0.54) LTA4HKIF11TSHRTDP1SMN1; SMN2
Phenetole SCHEMBL18492 0.76
Phenetole SCHEMBL10779391 0.76 LTA4H (0.81) LTA4HNQO1RELATSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1532160-A2 ANTISENSE MODULATION OF INSULIN-LIKE GROWTH FACTOR 2 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2005-05-25 EP disclosed
WO-2004005461-A2 ANTISENSE MODULATION OF INSULIN-LIKE GROWTH FACTOR 2 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed
WO-2003104397-A2 ANTISENSE MODULATION OF G PROTEIN-COUPLED RECEPTOR KINASE 6 EXPRESSION ISIS PHARMACEUTICALS INC. (US) 2003-12-18 WO disclosed
WO-2003050133-A1 ANTISENSE MODULATION OF ESTROGEN RECEPTOR BETA EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2003-06-19 WO disclosed
WO-2003050244-A2 ANTISENSE MODULATION OF G PROTEIN-COUPLED RECEPTOR ETBR-LP-2 EXPRESSION ISIS PHARMACEUTICALS INC. (US) 2003-06-19 WO disclosed
EP-1289911-A2 UNIVERSAL SOLID SUPPORTS FOR SOLID PHASE OLIGOSYNTHESIS AND METHODS FOR THEIR PREPARATION AND USE Proligo LLC (US) 2003-03-12 EP disclosed
WO-2003000707-A9 ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION ISIS PHARMACEUTICALS INC (US) 2003-01-30 WO disclosed
WO-2001096357-A2 UNIVERSAL SOLID SUPPORTS FOR SOLID PHASE OLIGOSYNTHESIS AND METHODS FOR THEIR PREPARATION AND USE PROLIGO LLC (US) 2001-12-20 WO disclosed